Clik here to view.
GlaxoSmithKline Dodges China Bullet, Dish-Disney Deal Remains Elusive, and 2...
GlaxoSmithKline (NYSE:GSK): Chinese authorities are apparently likely to charge executives of GlaxoSmithKline on allegations of corruption, though the company as a whole will be spared, Reuters is...
View ArticleClik here to view.
Will GlaxoSmithKline Get Away in China?
Earlier this summer, pharmaceutical giant GlaxoSmithKline (NYSE:GSK) was slammed with accusations of bribery in its Chinese operations. Chinese authorities said Glaxo funneled $489 million in cash...
View ArticleClik here to view.
GlaxoSmithKline Drug Falls Short, Sarepta Shares Collapse, and 3 More Hot Stocks
GlaxoSmithKline (NYSE:GSK): GlaxoSmithKline has announced that its darapladib treatment failed to lower the risk of heart attack or stroke among chronic heart disease patients. Glaxo bought the rights...
View ArticleClik here to view.
Sony’s PS4 Moves by the Million, Twitter Gets Slapped with a Sell, and 3 More...
Sony Corp. (NYSE:SNE): In its first 24 hours on the open market, Sony’s PlayStation 4 gaming console moved more than 1 million units, with the company maintaining that ”sales remain very strong in...
View ArticleClik here to view.
Cantor Cools on Twitter, Wendy’s Restaurant Sale, and 3 More Hot Stocks
Twitter Inc. (NYSE:TWTR): Though he commends Twitter’s future potential, Cantor analyst Youssef Squali has pulled his Buy rating on the stock, citing valuation concerns. ”While we’re impressed with...
View ArticleClik here to view.
Damage Control: Glaxo CEO Goes to China
GlaxoSmithKline (NYSE:GSK) CEO Andrew Witty is visiting China on a trade trip in order to reaffirm the company’s commitment to doing business in the country after a bribery scandal rocked Glaxo’s...
View ArticleClik here to view.
GlaxoSmithKline Has Big Hopes in This Market
GlaxoSmithKline (NYSE:GSK) is investing early in India’s booming pharmaceutical market. The company announced Monday that it is initiating a $1 billion voluntary open offer for a higher stake in its...
View ArticleClik here to view.
GlaxoSmithKline Wins ‘Breakthrough Therapy’ Status from FDA
The Food and Drug Administration on Friday granted GlaxoSmithKline (NYSE:GSK) and Medicines for Malaria Venture “breakthrough therapy” designation for the malaria drug tafenoquine, which is intended...
View ArticleClik here to view.
GlaxoSmithKline Scraps Rights to Failed Muscular Dystrophy Drug
Pharmaceutical giant GlaxoSmithKline (NYSE:GSK) has turned over the rights to drisapersen, a drug in development for the treatment of Duchenne muscular dystrophy, back to Prosensa Holding NV...
View ArticleClik here to view.
GlaxoSmithKline Wins Another FDA ‘Breakthrough’ Designation
GlaxoSmithKline (NYSE:GSK) was again granted “breakthrough therapy” status by the Food and Drug Adminsitration on Monday, this time for a drug called eltrombopag (also known as Promacta or Revolade),...
View Article